Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Eli Lilly and Company (NYSE: LLY) has announced the successful completion of its acquisition of Centessa Pharmaceuticals plc, a clinical-stage biopharmaceutical company focused on developing new treatments for sleep-wake disorders, including narcolepsy. The deal, finalized on June 24, 2026, involves an undisclosed amount and is expected to enhance Lilly's capabilities in addressing significant unmet medical needs in this therapeutic area.

Centessa Pharmaceuticals has established itself as a key player in the development of orexin receptor 2 agonists, a novel class of medicines aimed at regulating the orexin system, which is crucial for maintaining wakefulness and sleep stability. The company’s clinical portfolio is designed to target narcolepsy and potentially other disorders linked to disrupted sleep patterns, addressing a critical gap in treatment options for patients suffering from these conditions. The acquisition aligns with Lilly’s strategic focus on expanding its neuroscience portfolio and advancing therapies that can significantly improve patients' quality of life.

Lilly's executive vice president, Carole Ho, highlighted the urgency of pursuing Centessa's innovative potential, emphasizing the severe impact of narcolepsy on patients' daily lives. The acquisition not only bolsters Lilly's existing pipeline but also positions the company to leverage Centessa's research capabilities to explore broader applications of orexin modulation in other sleep-related disorders. This move reflects a growing recognition of the importance of sleep health in overall well-being and the need for effective treatments in this space.

The broader implications of this acquisition extend to the pharmaceutical sector, particularly in the realm of neuroscience and sleep medicine. As the demand for effective treatments for sleep disorders continues to rise, driven by increasing awareness and diagnosis rates, the integration of Centessa’s assets into Lilly’s operations may accelerate the development of groundbreaking therapies. Furthermore, this transaction underscores the trend of larger pharmaceutical companies seeking to enhance their portfolios through targeted acquisitions, particularly in specialized areas with significant unmet needs.

Overall, the acquisition of Centessa Pharmaceuticals by Eli Lilly represents a strategic move to strengthen Lilly's position in the neuroscience sector and enhance its offerings in sleep-wake disorder treatments. As the market for sleep medicine evolves, this acquisition may pave the way for innovative solutions that address the complexities of sleep health, ultimately benefiting millions of patients worldwide.